InsidersTradesSigma
申报总数
公司
▲ 买入（2 笔）
▼ 卖出（2 笔）
内部人交易记录
高级管理人员已披露买入
2
已披露卖出
2
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the complete record of transactions filed by Gaynor Richard, Director. Insider active across 2 companies, notably Zai Lab Ltd. In total, 16 disclosures have been logged. Split: 2 buys · 2 sells. Total volume traded: €184k. Activity tracked since 20 May 2021. The latest transaction was disclosed on 1 July 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Gaynor Richard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报16 总计
1,736 股@ US$19.050.0015% mcap4.3% 占其流量American Depositary SharesSEC:0000905148-26-003169:0
标准退出：2026年9月29日 (T+90)
6,142 股Ordinary SharesSEC:0001520262-26-000084:0
1,475 股@ US$36.950.0010% mcap100.0% 占其流量Ordinary SharesSEC:0001520262-26-000084:1
1,731 股@ US$18.910.0012% mcap50.0% 占其流量American Depositary SharesSEC:0000905148-26-001398:0
标准退出：2026年6月15日 (T+90)
10,831 股0American Depositary SharesSEC:0000905148-25-002217:0
8,013 股Ordinary SharesSEC:0001127602-25-016198:0
2,500 股@ US$35.0712.8% 占其流量American Depositary SharesSEC:0000905148-25-000873:0
2,500 股@ US$19.506.9% 占其流量American Depositary SharesSEC:0000905148-24-002519:0
6,104 股Ordinary SharesSEC:0001127602-24-019594:0
21,253 股0American Depositary SharesSEC:0000905148-24-001753:0
5,957 股Ordinary SharesSEC:0001127602-23-020547:0
18,903 股@ US$26.4571.5% 占其流量American Depositary SharesSEC:0000950170-23-031095:0
7,585 股Ordinary SharesSEC:0001127602-22-017637:0
5,578 股Ordinary SharesSEC:0001127602-21-030302:0
8,912 股0Ordinary SharesSEC:0000899243-21-045487:0
6,104 股0Ordinary SharesSEC:0001127602-21-017788:0
16 条申报中的 16 条
About Gaynor Richard
Richard Gaynor is a Director at Zai Lab Ltd and Alkermes plc. He brings valuable expertise in corporate governance and strategy. As a board member, he is involved in overseeing the operations and strategic decisions of the companies. His experience in the pharmaceutical and biopharmaceutical sectors enables him to effectively contribute to the growth and innovation of the organizations he serves.
